Update on osteoporosis treatment.

Med Clin (Barc)

CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES) Instituto Carlos III, Madrid, España; Universitat Autònoma de Barcelona, Barcelona, España; Atenció Primària Barcelona Ciutat, Institut Català de la Salut, Barcelona, España; Grupo de Investigación GREMPAL, Instituto Universitario de Investigación en Atención Primaria Jordi Gol, Barcelona, España.

Published: June 2018

Treatment of osteoporosis should be directed primarily towards secondary prevention of fractures. The occurrence of drug-related adverse effects for the treatment of osteoporosis has led to a reevaluation of the indications, the duration of treatment and even withdrawal of some drugs from the market. This review has been made from different patient profiles that practitioners will find in usual practice; from patients with hip fracture with cognitive impairment, limitation of their day-to-day living activities and comorbidities, to active patients without any limitations; patients with vertebral fractures and non-vertebral fractures where secondary prevention is highly important. In general, antiresorptive drugs (alendronate and risedronate) will be the first choice. Zoledronate or denosumab will be indicated in cases of digestive intolerance, poor adherence or an increased risk of hip fracture. Teriparatide will be indicated to patients with 2or more previous vertebral fractures or very low bone density.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2017.10.019DOI Listing

Publication Analysis

Top Keywords

treatment osteoporosis
8
secondary prevention
8
hip fracture
8
vertebral fractures
8
will indicated
8
update osteoporosis
4
treatment
4
osteoporosis treatment
4
treatment treatment
4
osteoporosis directed
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!